References
- Franco S, Hammerschlag MR. Neonatal ocular prophylaxis in the United States: is it still necessary? Exp Rev Anti-Infective Ther. 2023;21(5):503–511. doi: 10.1080/14787210.2023.2172401
- CDC -. STD Treatment - Drug notices. cited 2021 Dec 13]. Available from: https://www.cdc.gov/std/treatment/drug-notices.htm
- Drug shortage detail: erythromycin ophthalmic ointment. [cited 2024 Mar 14]. Available from: https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=850&loginreturnUrl=SSOCheckOnly
- NDC List. Ndc 72485-670 erythromycin. 2024 [cited 2024 Mar 15]. Available from: https://ndclist.com/ndc/72485-670#footnote-start-marketing-date
- FERA Dear Healthcare Provider Letter for Erythromycin | FDA. cited 2024 Mar 11]. Available from: https://www.fda.gov/media/173348/
- FDA Drug Shortages. cited 2024 Mar 21]. Available from: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Erythromycin%20Ointment&st=c
- Workowski KA, Bachmann LH, Chan P.A. Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. doi: 10.15585/mmwr.rr7004a1
- Curry SJ, Krist AH, Owens DK. US preventative services task force. Ocular prophylaxis for gonococcal ophthalmia neonatorum US preventative services task force reaffirmation recommendation statement. JAMA. 2019;321(4):394–398. doi: 10.1001/jama.2018.21367
- Smith-Norowitz T, Ukaegbu C, Kohlhoff S, et al. Neonatal prophylaxis with antibiotic containing ointments does not reduce incidence of chlamydial conjunctivitis in newborns. BMC Infect Dis. 2021;21(1):270. doi: 10.1186/s12879-021-05974-3
- WHO Guidelines for the Treatment of Neisseria gonorrhoeae. (WHO guidelines approved by the guidelines review committee). Geneva Switzerland: World Health Organization; 2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK379221/
- CDC -. Guidance on shortage of erythromycin (0.5%) ophthalmic ointment. [cited 2009 Sep]. Available from: http://www.cdc.gov/std/treatment/2006/erythromycinOintmentShortage.htm
- Binenbaum G, Bruno CJ, Forbes BJ, et al. Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns. J Pediatr. 2010;156(2):320–321. doi: 10.1016/j.jpeds.2009.11.060
- Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. Morbid Mortal Weekly Rep MMWR. 2010;59(RR–12):1–109.
- American Academy of Pediatrics. Committee on Infectious Diseases. Red Book : Report of the Committee on Infectious Diseases. 31sted. Elk Grove Village, IL: American Academy of Pediatrics; 2018.
- Rooney AM, Timberlake K, Brown KA, et al. Each additional day of antibiotics is associated with lower gut anaerobes in neonatal intensive care unit patients. Clin Infect Dis. 2020;70(12):2553–2560. doi: 10.1093/cid/ciz698
- Singh V, Lee G, Son H, et al. Butyrate producers, “The Sentinel of Gut”: Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Front Microbiol. 2023;13:1103836. doi: 10.3389/fmicb.2022.1103836
- Kapoor VS, Evans JR, Vedula SS. Interventions for preventing ophthalmia neonatorum (Review). Cochrane Database Syst Rev. 2020;9(CD001862):1–234. doi: 10.1002/14651858.CD001862.pub4
- Utine CA, Utine C. Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections. OPTH. 2011;5:801–809. doi: 10.2147/OPTH.S13785
- Tzialla C, Auriti C, Aversa S, et al. Intersociety position statement on the prevention of ophthalmia neonatorum in Italy. Microorganisms. 2024;12(1):15. doi: 10.3390/microorganisms12010015
- Hammerschlag MR, Gelling M, Roblin PM, et al. Treatment of neonatal chlamydial conjunctivitis with azithromycin. Pediatr Infect Dis J. 1998;17(11):1049–1050. doi: 10.1097/00006454-199811000-00020
- Holderman JL, Thomas JC, Schlanger K, et al. Sustained transmission of Neisseria gonorrhoeae with high-level resistance to azithromycin, in Indianapolis, Indiana, 2017-2018. Clin Infect Dis. 2021;73(5):808–815. doi: 10.1093/cid/ciab132
- AZASITE ® (Azithromycin Ophthalmic Solution) 1% Sterile Topical Ophthalmic Drops FULL PRESCRIBING INFORMATION. [cited 2024 Mar 19]. Available from: https://theapharmainc.com/wp-content/uploads/2022/12/azasite-pi.pdf
- Garnock-Jones KP. Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis. Drugs. 2012;72(3):361–373. doi: 10.2165/11208580-000000000-00000
- Granet D, Lichtenstein SJ, Onofrey B, et al. Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis. Clin Ophthalmol. 2008;2(1):241–242. doi: 10.2147/opth.s2819
- Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1(1):3–10.
- Committee for Human Medicinal Products (CHMP) questions and answers on benzalkonium chloride used as an excipient in medicinal products for human use. Published 2017. [cited 2024 Mar 18]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzalkonium-chloride-used-excipient-medicinal-products-human-use_en.pdf
- American Academy of Pediatrics. Committee on Infectious Diseases. Red Book : Report of the Committee on Infectious Diseases. 32nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2021.
- Derbie A, Mekonnen D, Woldeamanuel Y, et al. Azithromycin resistant gonococci: a literature review. Antimicrob Resist Infect Control. 2020;9(1):138. doi: 10.1186/s13756-020-00805-7
- Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613. doi: 10.1128/CMR.00010-14
- Slaney L, Chubb H, Ronald A, et al. In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother. 1990;25(suppl A):1–5. doi: 10.1093/jac/25.suppl_A.1
- Selb R, Buder S, Dudareva S, et al. Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021. Euro Surveill. 2021;26(31):2100616. doi: 10.2807/1560-7917.ES.2021.26.31.2100616
- Lahra MM, Hurley, van Hal Sj S, et al. National Neisseria Network, Australia. Australian gonococcal surveillance programme annual report, 2022. Commun Dis Intell. 2023;47:1–15. doi: 10.33321/cdi.2023.47.30
- National surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae – 2015. 2015 [cited 2024 May 5]. Available from: https://www.canada.ca/en/public-health/services/publications/drugs-health-products/national-surveillance-antimicrobial-susceptibilities-neisseria-gonorrhoeae-annual-summary-2015.html
- Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance - the gonococcal isolate surveillance project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016;65(7):1–19. doi: 10.15585/mmwr.ss6507a1
- Workowski KA, Bolan G.A. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(33):924.
- SURRG Working Group, Gieseker KE, Learner ER, Mauk K, et al. Demographic and epidemiological characteristics associated with reduced antimicrobial susceptibility to Neisseria gonorrhoeae in the United States, strengthening the US response to resistant gonorrhea, 2018 to 2019. Sex Transm Dis. 2021;48(12S):S118–S123. doi: 10.1097/OLQ.0000000000001541
- Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS. 1997;8(5):299–302. doi: 10.1258/0956462971920127
- Kong FYS, Horner P, Unemo M, et al. Pharmacokinetic considera- tions regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother. 2019;74(5):1157–1166. doi: 10.1093/jac/dky548
- Stewart WC, Crean CS, Zink RC, et al. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Am J Ophthalmol. 2010;150(5):744–751.e2. doi: 10.1016/j.ajo.2010.05.039
- Bremond-Gignac B-GD, Chiambaretta F, Milazzo S, et al. A European perspective on topical ophthalmic antibiotics: current and evolving options. Ophthalmol Eye Dis. 2011;3:29–43. doi: 10.4137/OED.S4866
- Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735–754. doi: 10.1007/s13346-016-0339-2
- Isenberg SJ, Apt L, McCarty J, et al. Development of tearing in preterm and term neonates. Arch Ophthalmol. 1998;116(6):773–776. doi: 10.1001/archopht.116.6.773
- OptumRxAzaSite (azithromycin). Belladonna and opium suppository – drug shortages. [cited 2024 Mar 19]. Available from: https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-recalls-shortages/drugshortages_azasite_belladonna_2018-0808.pdf
- Centers for Disease Control and Prevention. CDC’s STI treatment guidelines timeline: the evolution of sexual healthcare. [cited 2024 Jan 30]. Available from: https://www.cdc.gov/std/treatment-guidelines/timeline.htm
- Ivensky V, Mandel R, Boulay A-C, et al. Suboptimal prenatal screening of Chlamydia trachomatis and Neisseria gonorrhoeae infections in a Montreal birthing and tertiary care centre: a retrospective cohort study. Can Commun Dis Rep. 2021;47(4):209–215. doi: 10.14745/ccdr.v47i04a05
- Moore DL, MacDonald NE. Canadian paediatric society, infectious diseases and immunization committee. Preventing ophthalmia neonatorum. Paediatr Child Health. 2015;20(2):93–96.
- Canadian Notifiable Diseases Surveillance System (CNDSS), Public Health Agency of Canada (PHAC). [cited 2024 Mar 25]. Available from: http://diseases.canada.ca/notifiable/charts?c=cc#c=cc&lang=en_US